Indications
Nulojix, in combination with corticosteroids and a mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.
Composition
- Active substance
- belatacept
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Nulojix
- Active substance
- belatacept
- ATC code
- L04AA28
- Therapeutic area
- Graft Rejection, Kidney Transplantation
- Marketing authorisation holder
- Bristol-Myers Squibb Pharma EEIG
- Status
- Authorised